Introduction: Diagnosis of prostatic diseases with Immunohistochemistry still faces challenges because of the peculiar histology of the prostate
Introduction
The prostate is the site of two of the most common diseases in elderly men, Benign Prostatic Hyperplasia (BPH) and Prostate cancer (CaP). Both of these conditions are disorders of cell differentiation and cell proliferation [1] . Prostate cancer is the second most frequently diagnosed cancer as well as the sixth leading cause of death in males worldwide [2] . Little is known about the basic biology of cell phenotypes in either normal prostate or prostatic cancers. Phenotypes that are intermediate between those of basal and luminal cells in the heterogeneous prostate epithelial cells have been reported [3] . The prostate gland contains epithelial cells expressing two major phenotypes: luminal and basal cells separated by basement membrane from the stroma. If appropriate makers can be used, characterization of the phenotypes of cells will thus represent a major advantage [4] .
The variety of morphologic patterns of different entities of the genitourinary tract can represent a diagnostic dilemma for the pathologist. This is especially true in cases that mimic cancer, in cancer of unknown primary or poorly differentiated tumors in which it is hard to assign histiogenesis needed to plan the correct therapy for the patient [5] . It has also observed that routine staining of prostatic lesions sometimes cause diagnostic dilemma especially in premalignant lesions like atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia (PIN) [6] .
The use of Immunohistochemistry in diagnosis is presently widespread because of its sensitivity and specificity. However, diagnosis of prostatic diseases with Immunohistochemistry is still facing challenges because of peculiar histology of the prostate and difference(s) in reactivity to Monoclonal antibodies (MoAb) by benign and malignant changes.
The expression of cytokeratins in prostatic epithelium is varied and is well recognized [7] . It has been reported that Immunohistochemistry offers a better capacity than Haematoxylin and eosin staining alone and its addition to the diagnostic armamentarium for genitourinary pathologic diagnosis has increased the sensitivity and specificity of diagnosis and aided in the selection of optional therapeutic regimens in selected cases [5] . The first study utilizing anti keratin monoclonal antibodies was reported [8] .
Others reported immunoreactivity of keratin in basal cell of normal and hyperplastic prostatic epithelium with no staining of adenocarcinoma [9, 10] . Conversely, keratin was identified in one case of prostatic adenocarcinoma using polyclonal anti serum raised against bovine muzzle pre-keratin [11] . It was further reported that keratin immunoreactivity differs in the two epithelial cells of the prostate, probably due to expression of different keratin proteins [12] .
Several biological markers have been reported in literature to be good objective markers of progression of different neoplasms. The Ki67 antigen is a useful proliferation marker [13] . The potential of Ki67 antibody for diagnostic purpose was investigated, assessing the proliferation activity in normal prostate tissue, Prostatic Intraepithelial Neoplasia and Prostatic Cancer patients [14] . Cell proliferation is a fundamental aspect of a number of prostatic diseases ranging from hyperplasia to neoplasia [14] . It was reported that cellular proliferation can be studied using Immunohistochemical and the antibodies applied for 45minutes after passing through peroxidise and protein blocks. The secondary biotin-labeled antibody was incubated for 15min at room temperature. The streptavidin labelled streptavidin-biotin amplification method was carried out for 30minutes followed by 3,3'-Diaminobenzidine (DAB) and haematoxylin counter stain were subsequently applied in sequence.
Reactivity was observed as brown coloration. Photomicrographs of reactive sections were taken.
The necessary institutional ethical clearance was sought and obtained from Meena Histopathology laboratory.
Results
The percentage of cases that expressed each of the monoclonal antibodies (MoAb) in BPH and CaP are presented in Table 1 
Discussion
The co-expression and individual expression of CK5/6, Ck7, Ck8, Ck20 and Ki67 in BPH and CaP was examined. This information intends to make distinction between benign and malignant diseases of the prostate clearer. Our study shows that majority of BPH samples were reactive to Ck5/6 (93.3%), Ck7 (80%) and Ck8 (100%) ( Table 1 ) and is agreeable with previous research [16] .
Only 13.3% of samples were reactive to Ki67. This is understandable because BPH is benign and Ki 67 is known to be a proliferative MoAb and is also consistent with previous reports [10, 17] . The observation of cytokeratins (Ck5/6and7) in a few CaP samples was noted. It was however, observed that this occurred only in poorly differentiated squamous cell carcinoma. The only case that was not reactive with the cytokeratins is the well differentiated squamous cell carcinoma. Other researchers [18, 19] Figure   2 and Ck5/6, 7,8 and Ki67 in13.3%; Ck7and Ki67 in 13.3% that cuts across BPH and CaP. It was also, observed that these coincided with samples that had a diagnosis of squamous cell carcinoma. This is significant in the differential diagnosis of squamous cell carcinoma of the prostate and Prostatic Adenocarcinoma.
Co-expression of MoAb in BPH and CaP is represented in

Conclusion
Definitive diagnosis of prostatic tumors using individual expression and co-expression of monoclonal antibodies is critical to the selection of options for therapeutic regimens and therefore the information obtained can be used although to a limited extent to make diagnosis more accurate. Consequently, the pathologist needs to be knowledgeable in the use of co-expressed antibodies to make decisions in diagnosis.
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